Hyland’s debuts natural product line for expo
ANAHEIM, Calif. Hyland’s Inc. announced Tuesday the debut of their new arnica-based Muscle Therapy line which is being showcased at this year’s 2009 Natural Products Expo West March 5-8.
“The products deliver effective, natural pain relief from sore, stiff and over-worked muscles allowing for a fast recovery,” stated J.P. Borneman, chairman and CEO of Hyland’s. “It’s a great solution for those who stay active and, like all of our products, the muscle therapy line will never cause any of the potentially harmful side effects of some conventional pain relief medications.”
Hyland’s arnica-based products provide natural pain relief for aches, pains, muscle soreness, bruising and inflammation that may occur with regular activities or workouts. The new line includes Arnica 30X Tablets; Muscle Therapy Strips with Arnica which come in a thin-strip delivery format; and a topical formulation Muscle Therapy Gel with Arnica.
In addition to their line of Muscle Therapy products, Hyland’s will showcase a new Soothe ‘n Sleep Kit. The Soothe ‘n Sleep Kit contains a bottle each of Hyland’s Calms Forte and Nerve Tonic, along with a free gift of a sheep stress ball key chain.
The products in the Muscle Therapy line, as well as the Soothe ‘n Sleep Kit, will be available in natural food stores, drug stores, and major retailers nationwide, the company stated.
OTC heartburn relief used in prevention of peptic ulcers
BEIJING A research team led by Satoshi Mochida from Japan addressed the incidence of low-dose aspirin-induced peptic ulcer in elderly individuals, concluding that the use of H2 receptor antagonists like Pepcid or proton pump inhibitors such as Prilosec OTC may help in reducing peptic ulcer associated with a low-dose aspirin therapy.
Their results indicated that H2RA therapy was effective for both the prevention and treatment of low-dose aspirin induced peptic ulcers, similar to the effects of PPIs, while cytoprotective anti-ulcer drugs were ineffective in preventing peptic ulcers.
The study was published on Feb. 14 edition of the World Journal of Gastroenterology.
Generic Pharmaceutical Association praises Pres. Obama’s budget proposal
ARLINGTON, Va. President Barack Obama’s budget proposal, which includes an approval pathway for biosimilars, won praise from the Generic Pharmaceutical Association last week.
“For patients across the country suffering from cancer, diabetes and other diseases, the support stated by president Obama today for a workable biogenerics approval pathway is lifesaving news,” GPhA president and CEO Kathleen Jaeger said in a statement. “With countless patients struggling to pay the high costs of brand biopharmaceuticals, an approval pathway for safe, effective and affordable biogeneric medicines that provides access sooner rather than later is desperately needed.”
The model that the Hatch-Waxman Act of 1984 established for generic drugs provides a five-year period of data exclusivity for branded pharmaceutical drugs, which GPhA favors for biosimilars as well. However, the Biotechnology Industry Organization favors a 14-year data exclusivity period, saying that the Hatch-Waxman model would not provide sufficient time for biotech companies to recoup research and development expenses, thus stifling innovation.